Molecular Neuropharmacology

K.M. Standifer, C.C. Chien, C. Wahlestedt, G.P. Brown, G.W. Pasternak, "Selective loss of delta-opioid analgesia and binding by antisense oligodeoxynucleotide to a delta-opioid receptor," Neuron, 12:805-10, 1994. (Cited in more than 30 publications as of February 1996) Comments by Gavril W. Pasternak, Memorial Sloan-Kettering Cancer Center Unzip a chunk of DNA. Two strands result. One, dubbed the "sense" strand, carries genetic information. The other, the antisense strand, says nothing. In th

Written bySteven Benowitz
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

K.M. Standifer, C.C. Chien, C. Wahlestedt, G.P. Brown, G.W. Pasternak, "Selective loss of delta-opioid analgesia and binding by antisense oligodeoxynucleotide to a delta-opioid receptor," Neuron, 12:805-10, 1994. (Cited in more than 30 publications as of February 1996)

Unzip a chunk of DNA. Two strands result. One, dubbed the "sense" strand, carries genetic information. The other, the antisense strand, says nothing.

In theory, scientists can use antisense molecules to block the production of a particular protein. Scientists construct antisense strands by stringing together DNA bases that are complementary to the messenger RNA (mRNA) encoding the protein. This mirror-image piece of genetic material, in binding to the mRNA, halts it from hooking up with a cell's protein-manufacturing machinery.

SENSIBLE: Gavril W. Pasternak uses antisense to study opioid receptors In this paper, Gavril W. Pasternak, head of the laboratory of molecular neuropharmacology at Memorial Sloan-Kettering Cancer Center in New York, and his coworkers ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies